Edith Cowan University

Research Online
Research outputs 2022 to 2026
1-1-2022

Changes in body composition in patients with malignant pleural
mesothelioma and the relationship with activity levels and dietary
intake
Emily Jeffery
Edith Cowan University, e.jeffery@ecu.edu.au

Y. C. Gary Lee
Edith Cowan University, gary.lee@uwa.edu.au

Robert U. Newton
Edith Cowan University, r.newton@ecu.edu.au

Philippa Lyons-Wall
Edith Cowan University, p.lyons-wall@ecu.edu.au

Joanne McVeigh

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2022-2026
Part of the Dietetics and Clinical Nutrition Commons, Diseases Commons, and the Sports Sciences
Commons
10.1038/s41430-021-01062-6
Jeffery, E., Gary Lee, Y. C., Newton, R. U., Lyons-Wall, P., McVeigh, J., Fitzgerald, D. B., ... Peddle-McIntyre, C. J.
(2022). Changes in body composition in patients with malignant pleural mesothelioma and the relationship with
activity levels and dietary intake. European Journal of Clinical Nutrition. Advance online publication.
https://doi.org/10.1038/s41430-021-01062-6
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworks2022-2026/94

Authors
Emily Jeffery, Y. C. Gary Lee, Robert U. Newton, Philippa Lyons-Wall, Joanne McVeigh, Deirdre B.
Fitzgerald, Leon Straker, and Carolyn J. Peddle-McIntyre

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworks2022-2026/94

European Journal of Clinical Nutrition

ARTICLE

www.nature.com/ejcn

OPEN

Nutrition in acute and chronic diseases

Changes in body composition in patients with malignant
pleural mesothelioma and the relationship with activity levels
and dietary intake
Emily Jeffery
Leon Straker

1,2,3 ✉
7

, Y. C. Gary Lee4,5,6, Robert U. Newton
and Carolyn J. Peddle-McIntyre1,2

1,2

, Philippa Lyons-Wall2, Joanne McVeigh7,8, Deirdre B. Fitzgerald4,

1234567890();,:

© The Author(s) 2022

BACKGROUND: Skeletal muscle loss is common in advanced cancer and is associated with negative outcomes. In malignant pleural
mesothelioma (MPM), no study has reported body composition changes or factors associated with these changes. This study aimed
to describe changes in body composition over time and its relationship with activity levels, dietary intake and survival.
METHODS: The study was a secondary analysis of data collected from a longitudinal observational study of patients with MPM.
Participants completed 3-month assessments for up to 18 months. Participants with two dual-energy x-ray absorptiometry (DXA)
scans were included. Changes in appendicular skeletal muscle mass (ASM) and total fat mass were used to categorise participants
into phenotypes. Activity levels were measured with an ActiGraph GT3X+ accelerometer and energy and protein intake was
measured with a 3-day food record and 24-h recall.
RESULTS: Eighteen participants were included (89% men, mean age 68.9 ± 7.1 years). Median time between DXA was 91 [IQR
84–118] days. Compared to participants with ASM maintenance (n = 9), fewer participants with ASM loss (n = 9) survived
≥12 months from follow-up (p = 0.002). Participants with ASM loss increased sedentary time (p = 0.028) and decreased light activity
(p = 0.028) and step count (p = 0.008). Activity levels did not change in participants with ASM maintenance (p > 0.05). Energy and
protein intake did not change in either group (p > 0.05).
CONCLUSIONS: Muscle loss was associated with poorer survival and decreased activity levels. Interventions that improve physical
activity or muscle mass could beneﬁt patients with MPM.
European Journal of Clinical Nutrition; https://doi.org/10.1038/s41430-021-01062-6

INTRODUCTION
Malignant pleural mesothelioma (MPM) is an incurable cancer that
results from asbestos exposure [1]. Patients with MPM have
limited treatment options and short median survival of 12 months
[1]. It has been hypothesised that cancer cachexia could
contribute to the cause of death in MPM [2].
Cancer cachexia is a form of malnutrition characterised by
the loss of skeletal muscle mass in the presence or absence of
loss of fat mass, and is often accompanied by anorexia and
systemic inﬂammation [3]. Cancer cachexia can lead to the
development of low skeletal muscle mass, which is associated
with a range of negative outcomes in advanced cancer
populations including poorer quality of life [4], lower activity
levels [5], increased treatment toxicity [6], and poorer survival
[6]. Further, people with both low skeletal muscle mass and
excess fat mass (i.e., sarcopenic obese) have had a greater risk
of negative outcomes [7].

In our previous research, we reported that 50% of patients with
MPM had low skeletal muscle mass close to the time of diagnosis,
and of these participants, 11% were obese [5]. While anecdotally
clinicians report that patients with MPM become emaciated over the
disease course, and often die with a low BMI [2], there is a lack of
evidence available on changes in body composition over time to
inform the development of interventions to address these concerns.
Physical activity and dietary intake are modiﬁable factors that
could be central to the development of cancer cachexia. Physical
activity and dietary protein intake stimulate muscle protein
synthesis [8] and in sufﬁcient quantities could protect against
the development of low skeletal muscle mass [9, 10]. In addition,
lower levels of physical activity and high dietary energy intake can
create a positive energy balance resulting in weight gain that is
largely an increase in fat mass [11]. At present, there is little
research on the relationship between physical activity, dietary
intake and changes in body composition in cancer populations.

1
Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia. 2School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA,
Australia. 3School of Population Health, Curtin University, Perth, WA, Australia. 4Respiratory Department, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. 5Institute for
Respiratory Health, Nedlands, WA, Australia. 6Medical School, University of Western Australia, Crawley, WA, Australia. 7School of Allied Health, Curtin University, Perth, WA,
Australia. 8Movement Physiology Laboratory, School of Physiology, University of Witwatersrand, Johannesburg, South Africa. ✉email: emily.jeffery@curtin.edu.au

Received: 4 February 2021 Revised: 14 November 2021 Accepted: 16 December 2021

E. Jeffery et al.

2
Understanding these relationships could lead to more targeted
interventions to prevent and treat cancer cachexia. Therefore, this
study in patients with MPM aimed to describe the changes in
body composition over time and the relationship between body
composition changes and activity levels and dietary intake. A
secondary aim of the study was to explore the association
between body composition changes and participant characteristics, such as survival.
METHODS
Study design and participants
The study was a secondary analysis of data collected from a longitudinal
observational study that aimed to describe the functional and nutritional
status of patients with MPM. Participants were recruited from a pleural
disease clinic in Perth, Western Australia. Patients were eligible if they had
cytological or histological conﬁrmation of MPM. Patients were excluded if
they were aged <18 years, pregnant or lactating, unable to read and
understand English, unable to comply with the protocol or participating in
an intervention study likely to inﬂuence body composition. Participant
consent and physician approval were required for participation in the
study. Participants completed assessments of body composition, activity
levels and dietary intake during routine hospital visits, approximately every
3 months and were followed until death or for a maximum of 18 months.
Participants that did not complete body composition scans at two
consecutive assessments were excluded from this analysis. The study was
approved by the Sir Charles Gairdner Group and Edith Cowan University
Human Research Ethics Committees (ID: 2014-124 and 13255).

Measurements
Demographic and medical variables. Demographic and medical data were
obtained from participant medical records. Disease progression at followup was determined by clinician examination of the computed tomography
scan completed closest to the second body composition scan. The Eastern
Cooperative Oncology Group (ECOG) performance status was recorded on
the date of assessment [12].
Anthropometric measures. Weight and height, measured with participants
dressed in light clothing with shoes removed, were used to calculate the
BMI. Participants were classiﬁed as underweight, normal weight, overweight or obese based on World Health Organisation BMI criteria [13].
Body composition. Body composition was assessed using whole-body
dual-energy x-ray absorptiometry (DXA) scans (Hologic Horizon A, Hologic
Inc., Marlborough, MA, USA). DXA is considered a precise measure of body
composition, with coefﬁcients of variation reported to be <0.5% for lean
mass, and <1.0% for fat mass [14]. Device calibration was completed daily
using the Hologic Spine Phantom [15]. Participants wore light clothing
with shoes removed, and were asked to remove all metal objects (i.e.,
glasses, jewellery). Participants were positioned in a supine position in the
centre of the table, their arms by their side and palms facing down, with
legs were shoulder-width apart and internally rotated [16]. Participants
who were unable to lie ﬂat were given a pillow to support their head [15].
Following the scan, measured weight was compared to total mass to check
for any discrepancies. DXA scans were analysed using the in-built scan
analysis software (version 13.5.2). To analyse appendicular skeletal muscle
and fat mass, a single researcher (EJ) manually corrected the separation of
body regions, so that the arms were separated at the acromio-humeral
joints and the legs were separated at the pelvic-femoral joints [17]. Low
skeletal muscle mass was deﬁned as BMI-adjusted appendicular skeletal
muscle mass of 0.86 kg/kg/m2 for men and 0.59 kg/kg/m2 for women [18].
The cut-points for appendicular skeletal muscle mass were derived from
Hologic DXA devices and set as two standard deviations below the mean
of a reference sample of young Australian adults [18]. Participants with low
skeletal muscle mass were categorised as having low muscularity [19].
Change in body composition variables was calculated as the per cent
change between the second and ﬁrst measurements.
To characterise changes in body composition over time, participants
were categorised into body composition phenotypes according to changes
in skeletal muscle mass and fat mass. The total lean mass measured with
DXA includes both skeletal muscle and residual mass (i.e., organs);
however, appendicular lean mass is predominantly skeletal muscle [20].
Therefore, to report on changes in skeletal muscle mass we used

appendicular lean mass, known as appendicular skeletal muscle mass,
which represents on average, 75% of whole-body skeletal muscle [20]. The
four body composition phenotypes were: (1) loss of appendicular skeletal
muscle mass and loss of total fat mass; (2) loss of appendicular skeletal
muscle mass and maintenance or gain of total fat mass; (3) maintenance or
gain of appendicular skeletal muscle mass and loss of total fat mass and (4)
maintenance or gain of appendicular skeletal muscle mass and
maintenance or gain of total fat mass. A loss was deﬁned as a change of
≥–1.45% for appendicular skeletal muscle mass and ≥–2.15% for total fat
mass between the ﬁrst and second measurements; maintenance or gain
was deﬁned as a change of <–1.45% for appendicular skeletal muscle mass
and <–2.15% for total fat mass between the ﬁrst and second measurements. These cut-points represent the minimal detectable change values
reported for total lean and fat mass in a study of Hologic DXA devices [14].
Activity levels. Sedentary behaviour and physical activity were devicederived following each body composition scan using the ActiGraph
GT3X+ accelerometer (Actigraph, Pensacola, FL, USA). The ActiGraph
GT3X+ accelerometer has been shown to have high intra- and inter-device
reliability, with coefﬁcients of variation ≤2.5% and an intraclass coefﬁcient
of 0.99 [21]. Participants were instructed to wear the accelerometer on
their hip 24 h/day for 3 days, to only remove for bathing or swimming and
to record any non-wear time in a logbook. Cut-points were applied to
classify sedentary behaviour as <100 counts/minute (cpm), light activity as
100–1952 cpm and moderate and vigorous physical activity (MVPA) as
>1952 cpm [22, 23]. Variables were calculated per day and then averaged
across all valid (at least 10 h of data) days. Additional accelerometer
methodology for this study has been reported previously [5].
Dietary intake. Dietary intake was measured following each body
composition scan using a 3-day estimated food record at the initial
assessment and a 24-h recall at subsequent assessments. These dietary
assessment methods are reported to accurately measure energy and protein
intake [24, 25]. Dietary intake data were collected, veriﬁed and analysed by a
dietitian with experience in dietary intake assessment. To assist participants
with the completion of the food record, written and verbal instructions were
provided explaining how to complete the food record and estimate portion
sizes using household measures. Returned food records were visually
inspected and incomplete details were clariﬁed with participants. Participants completed the 24-h recall in a face-to-face interview with a dietitian.
24-h recalls were conducted per the multiple pass method [25]. The food
records and 24-h recalls were analysed using Foodworks 8 software (Xyris
Software Pty Ltd, Queensland, Australia). Intake variables were calculated
per day, and for the food records, intake was averaged across all days.
Energy and protein intake were expressed as kJ or g per kg of body weight
per day.

Statistical analyses
Statistical analyses were conducted using the Statistical Package for the
Social Sciences (v. 23, IBM Corporation, Somers, NY, USA). Data were
expressed as mean (SD) or median [IQR] where the data were not normally
distributed. To examine the relationship between changes in body
composition and participant characteristics, activity levels and dietary
intake, participants were condensed into two groups: (1) participants with
a change of ≥–1.45% in appendicular skeletal muscle mass, deﬁned as the
muscle loss group; and (2) participants with a change of <–1.45% in
appendicular skeletal muscle mass, deﬁned as the muscle maintenance
group. Fisher’s exact test was used to test for differences in characteristics
between participants with muscle loss and muscle maintenance where the
data were categorical. As the data were not normally distributed, the
Mann–Whitney test was used to test for differences in characteristics
between participants with muscle loss and muscle maintenance where the
data were continuous, and for differences in change in activity levels and
dietary intake between muscle groups. The Wilcoxon signed-rank test was
used to test for differences in body composition, activity levels and dietary
intake between the ﬁrst and second measurements.

RESULTS
Participant characteristics
Of the 36 patients recruited to the longitudinal observational
study, 18 (50%) were included in this study (Fig. 1). The median
time between the ﬁrst and second body composition scans was 91
[84–118] days. Participant characteristics are presented in Table 1.
European Journal of Clinical Nutrition
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Fig. 1

Study ﬂowchart. Participants included and excluded in the study.

Table 1.

Participant characteristics, n = 18.
All participants (n = 18)

Muscle loss (n = 9)

Muscle maintenance (n = 9)

p value

Age, years

68.9 ± 7.1

65.0 [61.0–74.5]

69.0 [63.0–75.0]

0.605

Sex, men

16 (88.9%)

8 (88.9%)

8 (100%)

0.471

BMI, kg/m2

25.2 [23.9–28.7]

26.1 [23.9–29.8]

24.6 [23.8–27.1]

0.258

Underweight

0 (0.0%)

0 (0.0%)

0 (0.0%)

–

Normal weight range

9 (50.0%)

3 (33.3%)

6 (66.6%)

BMI category

Overweight

7 (38.9%)

4 (44.4%)

3 (33.3%)

Obese

2 (11.1%)

2 (22.2%)

0 (0.0%)

Low muscularity, yes

11 (61.1%)

6 (66.6%)

5 (55.6%)

Histological subtype, epithelioid

15 (83.3%)

7 (77.8%)

8 (88.9%)

1.000

ECOG performance status at ﬁrst scana, 0–1

18 (100%)

9 (100%)

9 (100%)

–

<3 months

10 (55.6%)

4 (44.4%)

6 (66.6%)

–

3–12 months

5 (27.8%)

3 (33.3%)

2 (22.2%)
1 (11.1%)

1.000

Time from diagnosis to ﬁrst scana

>12 months

3 (16.7%)

2 (22.2%)

Time from ﬁrst to second scan, days

91.0 [84.0–118.0]

85.0 [81.0–94.0]

98.0 [87.0–140.0]

0.113

Cancer treatment during follow-up, yes

9 (50.0%)

4 (44.0%)

5 (55.6%)

1.000

2 (40.0%)

–

Type of cancer treatment
Cisplatin and pemetrexed

3 (33.3%)

1 (25.0%)

Carboplatin and pemetrexed

3 (33.3%)

1 (50.0%)

2 (40.0%)

Vinorelbine

1 (11.1%)

1 (25.0%)

0 (0.0%)

Clinical trial—cisplatin, pemetrexed, and durvalumab

2 (22.2%)

1 (25.0%)

1 (20.0%)

Progressed

10 (55.6%)

5 (55.6%)

Stable

4 (22.2%)

2 (22.2%)

Disease progression at second scana
5 (55.6%)

–

2 (22.2%)

Response to treatment

2 (11.1%)

0 (0.0%)

2 (22.2%)

Data not available

2 (11.1%)

2 (22.2%)

0 (0.0%)

Time from second scana to death
<12 months

7 (38.9%)

7 (77.8%)

0 (0.0%)

≥12 months

11 (61.1%)

2 (22.2%)

9 (100.0%)

a

First or second body composition scan.
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Fig. 2 Proportion of participants within each body composition phenotype. (1) Loss of appendicular skeletal muscle mass and loss of total
fat mass; (2) loss of appendicular skeletal muscle mass and maintenance or gain of total fat mass; (3) maintenance or gain of appendicular
skeletal muscle mass and loss of total fat mass; and (4) maintenance or gain of appendicular skeletal muscle mass and maintenance or gain of
total fat mass.

The majority of participants were men (89%) and the mean age of
participants was 68.9 (7.1) years. Nine participants (50%) received
cancer treatment during the follow-up period. Nine participants
(50%) met the criteria for muscle loss and nine participants (50%)
met the criteria for muscle maintenance. Seven participants (78%)
with muscle loss survived less than 12 months from the second
body composition scan, while none of the participants (0%) with
muscle maintenance survived less than 12 months from the
second body composition scan (p = 0.002). For some outcomes
presented (e.g., cancer treatment status) the sample size was too
small to complete statistical analysis. No other differences in
participant characteristics were observed between muscle change
groups (p > 0.05) (Table 1).
Changes in muscularity status
Ten participants (56%) had low muscularity at the ﬁrst and second
body composition scans. One participant (14%) with normal
muscularity at the ﬁrst measurement had low muscularity at the
second scan. One participant (9%) who had low muscularity at the
ﬁrst measurement had normal muscularity at the second scan. Of
the participants with low muscularity, two (18%) were obese.
Changes in body composition
When participants were condensed into the four body composition phenotypes, seven participants (39%) had a loss of
appendicular skeletal muscle and fat mass, two participants
(11%) had a loss of appendicular skeletal muscle and maintained
fat mass, four participants (22%) maintained appendicular skeletal
muscle and lost fat mass and, ﬁve participants (28%) maintained
appendicular skeletal muscle and fat mass (Fig. 2).
There were no signiﬁcant changes in total, lean or fat mass
during the follow-up period in the whole group (Table 2).
Participants with muscle loss (n = 9) experienced a signiﬁcant
decrease in total mass (p = 0.008), trunk lean mass (p = 0.011),
appendicular skeletal muscle mass (p = 0.008) and trunk fat mass
(p = 0.021) but not appendicular fat mass (p = 0.859). Participants
with muscle maintenance (n = 9) experienced a signiﬁcant
increase in appendicular skeletal muscle mass (p = 0.038) but
not total mass (p = 0.31) trunk lean mass (p = 0.594), trunk fat
mass (p = 0.767) or appendicular fat mass (p = 0.594).
Change in activity levels according to muscle change group
There were no signiﬁcant changes in activity levels during the
follow-up period in the whole group (Table 3). Participants with
muscle loss had a signiﬁcant decrease in median step count (p =
0.008), an increase in the proportion of waking hours spent as
sedentary (p = 0.028) and a decrease in the proportion of waking
hours spent in light activity (p = 0.028) (Table 3). There was no

signiﬁcant change in the proportion of waking hours spent in
MVPA (p = 0.260). Participants with muscle maintenance maintained step count (p = 0.176), the proportion of waking hours
spent as sedentary (p = 0.499), in light activity (p = 0.499) and in
MVPA (p = 0.176) (Table 3).
There was a signiﬁcant difference between participants with
muscle loss and muscle maintenance for change in step count
(–1020 [–4667 to 56] vs. 1234 [–204 to 2221] steps/day; p = 0.008;
Fig. 3) and for the proportion of waking hours spent in light
activity (–4.8 [–9.2 to 0.2] vs. –0.7 [–2.0 to 7.5]; p = 0.023; Fig. 3) but
not for the proportion of waking hours spent as sedentary (4.9
[–2.3 to 11.1] vs. 0.5 [–8.6 to 2.2]; p = 0.142; Fig. 3).
Change in dietary intake according to muscle change group
There were no signiﬁcant within-group changes in energy and
protein intake during the follow-up period in the whole group
(Table 3). Participants with muscle loss and those with muscle
maintenance had no signiﬁcant change in energy and protein
intake (Table 3).
There was a signiﬁcant difference between participants with
muscle loss and muscle maintenance for change in protein intake
(–0.29 [–0.55 to 0.02] vs. 0.60 [–0.03 to 0.81] g/kg/day; p = 0.011;
Fig. 3) but not for change in energy intake (–5.8 [–46.1 to –0.03] vs.
9.4 [–22.5 to 103.6] kJ/kg/day; p = 0.236; Fig. 3).
DISCUSSION
Our study is the ﬁrst to prospectively assess changes in body
composition in relation to activity levels and dietary intake in
patients with MPM. We identiﬁed multiple patterns of body
composition change among our participants. Notably, participants
with muscle loss and muscle maintenance had distinct survival,
physical activity and dietary intake characteristics.
Our participants could be categorised across all four body
composition phenotypes. The most common phenotype, which
included 39% of participants, was the loss of appendicular skeletal
muscle mass and fat mass, which is consistent with the cachexia
phenotype [3]. When we condensed these body composition
phenotypes to two groups: (1) muscle loss and (2) muscle
maintenance; 50% of participants had muscle loss and 50% had
muscle maintenance. This result is particularly notable as the low
mean BMI reported in a post-mortem study indicates patients with
MPM become emaciated over the disease course [2]. While muscle
loss was common, our results suggest that a proportion of
participants with MPM can maintain muscle, at least for a
proportion of the disease course.
There were signiﬁcant differences in survival between participants with muscle loss and muscle maintenance. Only a small
European Journal of Clinical Nutrition
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0.594
10.1 (7.5–14.0)
10.2 (8.2–13.0)
0.859
11.5 (8.7–14.2)
11.9 (8.3–15.2)
0.679
11.5 (8.4–13.9)
11.3 (8.3–13.8)
Appendicular

Data are presented as median (interquartile range).
*p < 0.05.

0.953

0.767
11.8 (7.7–17.0)

23.6 (16.2–31.1)
22.9 (16.8–30.1)

11.9 (7.8–15.5)
0.021*

0.066
24.3 (20.5–28.0)

10.8 (9.4–14.0)
12.4 (10.1–15.3)

25.9 (20.1–30.1)
0.215

0.184

24.2 (19.8–28.7)
24.3 (20.1–30.1)

12.3 (9.8–15.1)

Total

Trunk

Fat mass

European Journal of Clinical Nutrition

11.2 (9.4–15.1)

0.011*

0.594
26.5 (24.8–28.2)

21.8 (20.3–22.2)
21.2 (18.5–22.0)

25.2 (24.7–28.9)
0.011*

0.008*
20.4 (17.3–21.8)

25.2 (23.8–29.0)
26.9 (25.2–29.9)

21.4 (18.6–23.0)

25.4 (24.5–28.3)

21.4 (18.9–22.2)

20.5 (19.7–22.2)

26.6 (24.8–29.1)
Trunk

Appendicular

0.085

50.8 (49.0–53.7)
49.6 (46.8–53.5)
0.008*
48.7 (43.9–54.6)
51.4 (46.9–56.4)
0.248
49.5 (46.9–53.9)
50.4 (47.3–53.9)
Total

Lean mass

0.306

0.038*

0.314
75.7 (68.8–90.9)

Second scan
First scan

74.1 (68.4–87.1)
0.008*

p value
Second scan

72.5 (66.9–88.7)
75.0 (70.4–91.6)

First scan
p value
First scan

75.0 (70.3–87.4)

Mass (kg)

Total

Second scan

0.133

Muscle loss (n = 9)
All participants (n = 18)

Participant changes in body composition, n = 18.

Table 2.

74.1 (67.3–88.7)

Muscle maintenance (n = 9)

p value

5
proportion (22%) of participants with muscle loss survived at least
12 months from the second body composition scan, while all
(100%) participants with muscle maintenance survived at least
12 months from the second body composition scan. Therefore,
muscle loss could be indicative of shorter survival in patients with
MPM. Similar ﬁndings have been reported in a large retrospective
study of patients with advanced cancer (n = 368) [26] where the
authors stated that muscle loss became more common as death
approached [26]. Tumour burden is thought to mediate the
metabolic changes that cause loss of muscle and fat mass [27],
highlighting the importance of efﬁcacious cancer treatments for
the management of cachexia [3]. There are currently limited
treatment options for those with MPM and only 40% of patients
respond to ﬁrst-line chemotherapy treatment [28]. Therefore,
addressing lifestyle factors that contribute to cancer cachexia
could offer beneﬁts to patients with MPM.
Participants with muscle loss had a signiﬁcant decline in
activity levels over the follow-up period of 3 months, while
participants with muscle maintenance maintained their activity
levels. As physical activity is required for muscle protein synthesis
[8], a decrease in physical activity may have contributed to
muscle loss among our participants. In addition, as the majority of
participants (70%) with muscle loss had low muscularity at followup, participants may not have had the strength and endurance to
participate in their usual physical activity. The lack of physical
activity could result in an even greater reduction in muscle loss.
Therefore, regardless of the causal pathway between muscle loss
and activity levels, resistance exercise training may offer beneﬁt
to patients with MPM as it can improve skeletal muscle mass,
strength and physical function [29].
There were no statistically signiﬁcant changes in dietary intake
over the follow-up period for participants with muscle loss and
muscle maintenance; however, we made clinically meaningful
observations. Participants with muscle loss had a median energy
and protein intake that was within the recommended energy and
protein intake range of 105–126 kJ/kg and 1.0–1.5 g/day, respectively [30], while median energy and protein intake among
participants with muscle maintenance exceeded these recommendations. A larger study (n = 52) in patients with incurable non-small
cell lung cancer (NSCLC) reported that higher energy and protein
intakes (149 kJ/kg and 1.4 g/kg, respectively) were associated with
maintenance of skeletal muscle mass during chemotherapy [31].
Approximately 40–50% of patients with NSCLC are reported to
have an elevated resting energy expenditure [32, 33], which could
lead to muscle and fat loss unless dietary intake is increased
proportionally. As muscle loss developed in our participants
meeting dietary intake recommendations, it is possible that
elevated resting energy expenditure exists to some extent in
patients with MPM. Intakes of energy and protein that exceed
recommendations may be needed to preserve skeletal muscle
mass in patients with MPM.
This study has several potential limitations worthy of consideration. There are several factors known to affect muscle and
fat metabolism, including disease progression, inﬂammation,
cancer treatment and older age [34]. As participants in this study
may be at different stages of the disease, combining all
participants together could have introduced bias to the ﬁndings.
While these characteristics were compared between participants
with and without muscle loss, the sample size was too small to
allow further evaluation concerning changes in body composition. Energy and protein intake at baseline and follow-up were
measured using different dietary assessment methods, which
could have affected the repeatability of the measurement.
Participant feedback indicated that a 3-day food record was
burdensome; therefore, we used 24-h recalls at follow-up
assessments. Compared with a 24-h recall, a 3-day food record
could be more representative of usual dietary intake as the
measurement is carried out over a greater number of days;
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Table 3.

Participant activity levels and dietary intake, n = 17.
All participants (n = 17)
First scan

Muscle loss (n = 9)

Muscle maintenance (n = 8)

Second scan

p value

First scan

Second scan

p value

First scan

Second scan

p value

Activity behaviours
Steps, n

5505
(4603–6404)

4736
(3608–6843)

0.196

6013
(4111–9117)

4251
(1738–5372)

0.008*

5039
(4582–5653)

5590
(4196–7404)

0.176

Sedentary
behaviour, %

70.3
(61.7–73.1)

73.1
(64.0–76.0)

0.196

67.0
(58.1–72.7)

73.7
(66.8–84.2)

0.028*

72.6
(62.8–73.2)

73.1
(63.4–75.7)

0.499

Light
activity, %

27.5
(26.4–35.0)

25.5
(22.3–34.5)

0.215

28.4
(26.0–39.6)

25.3
(15.4–30.8)

0.028*

27.1
(26.3–35.1)

26.2
(22.7–35.7)

0.499

MVPA, %

0.8 (0.5–3.1)

0.9 (0.7–1.7)

0.836

1.0 (0.4–5.3)

0.7 (0.3–1.5)

0.260

0.6 (0.5–1.4)

1.7 (0.8–1.7)

0.398

Energy
intake, kJ/kg

129.6
(90.1–143.8)

121.8
(102.3–147.2)

0.981

122.0
(83.2–138.6)

116.2
(81.7–127.4)

0.314

136.8
(103.1–151.1)

142.0
(110.2–245.5)

0.263

Protein
intake, g/kg

1.5 (0.9–2.0)

1.4 (1.1–1.8)

0.492

1.0 (0.9–1.9)

1.2 (0.7–1.4)

0.260

1.5 (1.0–2.0)

1.7 (1.4–2.7)

0.069

Dietary intake

Data are presented as median (interquartile range).
MVPA moderate and vigorous physical activity.
*p < 0.05.

Fig. 3 Change in physical activity and dietary intake according to muscle change group. a Step count; b proportion of waking hours as
sedentary; c proportion of waking hours in light activity; d energy intake (kJ/kg); and e protein intake (g/kg). *p < 0.05.

however, a 24-h food recall is not less accurate than a food record
[25]. Considering this population of advanced cancer patients,
participant burden was a key consideration in our study that
should also be taken into account in future investigations.
Our study provides an initial insight into changes in body
composition experienced by patients with MPM; however, further
research is needed to understand the factors that contribute to

the maintenance or decline of physical activity and dietary intake
over time. A strength of our study is the use of DXA for body
composition analysis, which enabled us to complete a reliable
evaluation of appendicular skeletal muscle mass and whole-body
and regional fat mass [20]. These data cannot be obtained
through computed tomography evaluation of body composition,
which employs a single cross-section analysis, and existing
European Journal of Clinical Nutrition
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prediction equations used to convert cross-sectional data to
appendicular skeletal muscle mass may be inaccurate [35]. In
addition, we report device-derived sedentary behaviour and
physical activity using an accelerometer, which has greater
accuracy when compared with self-report questionnaires [36].
CONCLUSION
For the ﬁrst time, we report on body composition changes over
time in patients with MPM. Our results indicate that multiple
patterns of change in body composition exist in this patient
population. Muscle loss was associated with poorer survival and
decreased activity levels. Interventions that improve physical
activity or muscle mass could beneﬁt patients with MPM.
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